European Medicines Agency statement on recent publication on cardiac safety of rosiglitazone (Avandia, Avandamet, Avaglim)

View source ↗

Summary

EMA issued a statement in response to a publication examining the cardiac safety of rosiglitazone-containing medicines (Avandia, Avandamet, Avaglim).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Avaglim (rosiglitazone)
• Avandamet (rosiglitazone/metformin)
• Avandia (rosiglitazone)